Liraglutide inhibits receptor for advanced glycation end products (RAGE)/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro

The study was designed to investigate the effects of liraglutide and reveal its action mechanism associated with RAGE/NAPDH in NAFLD. The liver tissue was collected for HE, Masson, and ROS staining. Apoptosis levels were detected through TUNEL staining and ROS levels were evaluated through ROS stain...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Jingquan, Feng, Ming, Huang, Yan, Niu, Xiaohong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974036/
https://www.ncbi.nlm.nih.gov/pubmed/35164657
http://dx.doi.org/10.1080/21655979.2022.2036902

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974036/
https://www.ncbi.nlm.nih.gov/pubmed/35164657
http://dx.doi.org/10.1080/21655979.2022.2036902

Ejemplares similares